STING1 and cancer: At present, the therapeutic application of STING agonists in tumors can be specifically targeted to specific cancer cells by intravenous injection of nanoparticles carrying STING agonists, which can cause a systemic immune response, as opposed to injecting STING agonists into specific cancer cells to induce a local immune response.